This call will explore the implications of the FDA's New Approach Methodologies initiative, focusing on the shift away from mandatory animal testing in drug development. It will cover the role of innovative technologies like organoids, organ-on-chip systems, and AI-driven models in advancing safer and more efficient preclinical research and their effects on drug development.